About Us.

We launch disruptive biotech ventures with a focus on disease-modifying genetic and cellular medicines. Genetic and anatomical repair of tissues is a commercially proven approach for treatment of life-threatening conditions. Correcting an underlying deficit within a cell or tissue can halt degeneration and potentially reverse the course of disease.

Highlighted Transactions.

$70+ Million Strategic R&D Alliance (2021)

Opsis Therapeutics: Bayer subsidiary BlueRock Therapeutics optioned three programs for an up-front, undisclosed milestone payments, and up to low-double digit tiered royalty

(2024 update: License of OpCT-001 & IND Clearance of OpCT-001)

$82 Million Series A Financing (2024)

Kenai Therapeutics: Financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group, with participation from Euclidean Capital and Saisei Ventures

Launched Companies.

Papillon Therapeutics Inc. is a clinical-stage biotechnology company advancing a pipeline of multi-systemic genetic medicines directed at the underlying causes of inherited disease. The company’s technology platform enables durable expression of functional protein throughout the body. Papillon was established by leading experts in genetic medicine, including Stephanie Cherqui, Ph.D.

StemCardia, Inc., is a biotechnology company advancing a pipeline of cellular and genetic medicines designed to restore and strengthen heart muscle tissue. Our mission is to develop and commercialize first-in-class medicines for treatment of heart failure, the leading cause of death. The company brings together experts in heart regeneration, leading clinical institutions, and a broad technology platform to advance a pipeline of transformative medicines.

Opsis Therapeutics is a company focused on advancing the pipeline of cell replacement therapies targeting ocular diseases. Leveraging innovations in induced pluripotent cell (iPSC) generation, retinal cell differentiation, and functional biomaterials, Opsis Therapeutics is developing cell therapies for patients with dry age-related macular degeneration (AMD), inherited macular degenerations (IMDs) and inherited retinal diseases (IRDs). Founded in 2016, Opsis Therapeutics is a joint venture of FUJIFILM Cellular Dynamics and David Gamm, M.D., Ph.D., and is headquartered in Madison, Wisconsin.

Vascugen is a regenerative medicine company engaged in the development of advanced therapies to treat incurable conditions caused by loss or degeneration of blood vessels. The company has exclusive, worldwide rights to a broad patent portfolio for its platform technology that enables the functional restoration of blood vessels in any organ or tissue, as well as rights covering related products and services for research, diagnostics, therapeutics, tissue engineering, organoid and 3D bio-printing applications. Driven by innovation and a team of scientific and clinical thought leaders, Vascugen was founded by Dr. Mervin C. Yoder, a pioneer and noted expert in the field of vascular stem cell biology.

RPRD (Right Patient Right Drug) Diagnostics is a precision medicine company offering clinical pharmacogenomics (PGx) testing and analysis services to healthcare providers and pharmaceutical companies worldwide. The Company is the PGx reference lab of choice for the leading pediatric cancer centers in the nation, as ranked by US News and World Report for 2019-2020. Results from RPRD Diagnostic’s PGx tests are used by healthcare providers to support clinical decision-making, thereby improving patient outcomes and reducing costs. The company specializes in both comprehensive PGx and tailored panels, such as the CNT Panel for identification of leukemia patients at risk for toxicity from thiopurine drugs. These tests enable physicians to consider a patient’s unique genetic profile when recommending drug treatment.

Dianomi Therapeutics was a development stage biopharmaceutical company advancing a pipeline of next generation treatments for inflammatory diseases, initially targeting osteoarthritis. The company’s proprietary Mineral Coated Microparticle (MCM) technology enables formulation of proven drugs for improved delivery, stability, and function.